Skip to NavigationSkip to content


Sales rise for AbbVie

Abbvie image

AbbVie has released its first financial results as a standalone company since separating from Abbott as an $18 billion biopharma company in its own right.

The two firms formally split apart at the start of the year, and - comparing the performance of those drugs now allocated to AbbVie from the first quarter of 2012 - AbbVie saw a sales rise of 3.7% to $4.3 billion.

AbbVie guards Humira data

Humira image

AbbVie has issued two injunctions against the European Medicines Agency to prevent the regulator revealing data about rheumatoid arthritis drug Humira.

Transparency is the mood music which backs most discussions of pharma at the moment, with companies being encouraged to make all trial data publically available.

But AbbVie objects to detailed patient data being made available to rivals, and has filed the legal actions in a bid to “protect AbbVie’s confidential and commercially-sensitive information”.

Abbott seeks leukemia test

Abbott image

Abbott is to team up with Janssen Biotech and biopharma firm Pharmacyclics to seek a diagnostic test for leukemia patients.

The trio of companies will see if Abbott’s FISH (fluorescence in situ hybridization) technology can be used to develop a test which would then be used in conjunction with a drug Janssen and Pharmacyclics are developing.

The goal is to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.

Abbott finishes strongly before spin-off

Abbott and AbbVie now go their separate ways

Abbott has presented its full-year results for 2012 – the last in which many of its products will appear, following the AbbVie split-off earlier this month.

While sales for the combined entity for the year were $39.9 billion, up just 2.6%, net profit rose 10.7% to $8.1 billion after $573 million of restructuring charges and $485 million of ‘separation’ cost was taken out.

AbbVie splits from Abbott

Abbott image

AbbVie, the new $18 billion biopharma company which includes many of Abbott’s most high profile products, has finally launched.

Abbott announced more than a year ago that it was to split into two publicly-traded companies, with AbbVie focusing on research-based pharma.

Humira powers ahead as Abbott prepares split

Humira image

Humira maintained its rapid growth in the second quarter, helping keep Abbott buoyant ahead of its split into two separate companies.

The rheumatoid arthritis drug saw its sales rise 16.5% to $4.2 billion in the period, growth that actually reached 23% if unfavourable currency moves are discounted.

Analysts want AstraZeneca-AbbVie tie-up

AZ image
AstraZeneca's HQ in London

Analysts want Abbott’s new spin-off firm AbbVie to merge with the troubled AstraZeneca, saying it could give both firms future value.

AbbVie will be the new R&D firm coming from Abbott’s split into two new companies, and is scheduled to go ahead within the next year.

Abbott sets out AbbVie stall for shareholders

Abbott image

Abbott Laboratories has issued the prospectus for its planned separation of its pharmaceutical operations into a standalone company called AbbVie later this year, noting this will include a contract manufacturing arm that will benefit from near-term supply revenue with Abbott.

The filing with the Securities & Exchange Commission notes that AbbVie had pro forma pharma sales of around $17.4 billion in 2011, an incre

Abbott pays $1.6 billion to settle Depakote claims

Depakote image

Abbott will pay $1.6 billion to settle US legal claims over its epilepsy drug Depakote. 

The $1.6 billion will settle claims by the US government that allege the firm illegally marketed Depakote for uses outside of its licence.

This includes marketing for: agitation and aggression in patients with dementia, autism, sexual compulsion, and other disorders.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches